Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results